{"prompt": "['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'Appendix 1:', 'Actions Required in Cases of Increases in Liver', \"Biochemistry and Evaluation of Hy's Law\", 'Introduction', 'This Appendix describes the process to be followed in order to identify and appropriately', \"report cases of Hy's Law. It is not intended to be a comprehensive guide to the management\", 'of elevated liver biochemistries.', 'During the course of the study the treating physician (i.e. Sub-Investigator, lead/Principal', 'Investigator) will remain vigilant for increases in liver biochemistry. The Principal', \"Investigator is responsible for determining whether a patient meets potential Hy's Law (PHL)\", 'criteria at any point during the study.', 'The Principal Investigator participates, together with AstraZeneca clinical project', \"representatives, in review and assessment of cases meeting PHL criteria to agree whether Hy's\", 'Law (HL) criteria are met. HL criteria are met if there is no alternative explanation for the', 'elevations in liver biochemistry other than Drug Induced Liver Injury (DILI) caused by the', 'Investigational Medicinal Product (IMP).', 'The Principal Investigator is responsible for recording data pertaining to PHL/HL cases and', 'for reporting Adverse Events (AE) and Serious Adverse Events (SAE) according to the', 'outcome of the review and assessment in line with standard safety reporting processes.', 'Definitions', \"Potential Hy's Law (PHL)\", 'Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) > 3x Upper Limit of', 'Normal (ULN) together with Total Bilirubin (TBL) > 2xULN at any point during the study', 'following the start of study medication irrespective of an increase in Alkaline', 'Phosphatase (ALP).', \"Hy's Law (HL)\", 'AST or ALT > 3x ULN together with TBL > 2xULN, where no other reason, other than the', 'IMP, can be found to explain the combination of increases, eg, elevated ALP indicating', 'cholestasis, viral hepatitis, another drug.', 'For PHL and HL the elevation in transaminases must precede or be coincident with (i.e. on the', 'same day) the elevation in TBL, but there is no specified timeframe within which the', 'elevations in transaminases and TBL must occur.', \"Identification of Potential Hy's Law Cases\", 'In order to identify cases of PHL it is important to perform a comprehensive review of', 'laboratory data for any patient who meets any of the following identification criteria in', 'isolation or in combination:', '85(93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'ALT > 3xULN', 'AST > 3xULN', 'The Principal Investigator will without delay review each new laboratory report, and if the', 'identification criteria are met will:', 'Determine whether the patient meets PHL criteria (see above) by reviewing', 'laboratory reports from all previous visits', 'Promptly enter the laboratory data into the laboratory eCRF', 'Follow-up', \"Potential Hy's Law Criteria not met\", 'If the patient does not meet PHL criteria the Principal Investigator will:', 'Perform follow-up on subsequent laboratory results according to the guidance', 'provided in the Clinical Study Protocol.', \"Potential Hy's Law Criteria met\", 'If the patient does meet PHL criteria the treating physician (i.e. Sub-Investigator, Principal', 'Investigator) will:', 'Notify the Principal Investigator who will notify AstraZeneca representative.', 'The treating physician (i.e. sub-investigator, Principal Investigator) contacts the', 'Principal Investigator, to provide guidance, discuss, and agree on an approach for', \"the study patient's follow-up and the continuous review of data. Subsequent to this\", 'contact the treating physician (i.e. sub-investigator, Principal Investigator) will:', 'Monitor the patient until liver biochemistry parameters and appropriate clinical', 'symptoms and signs return to normal or baseline levels, or as long as medically', 'indicated.', 'Investigate the etiology of the event and perform diagnostic investigations as', 'discussed with the Study Physician.', 'Complete the 3 Liver eCRF Modules as information becomes available.', 'If at any time (in consultation with the treating phsyician) the PHL case meets', 'serious criteria, report it as an SAE using standard reporting procedures', \"Review and Assessment of Potential Hy's Law Cases\", 'The instructions in this Section should be followed for all cases where PHL criteria are met.', 'No later than 3 weeks after the biochemistry abnormality was initially detected, the treating', 'physician contacts the Principal Investigator in order to review available data and agree on', 'whether there is an alternative explanation for meeting PHL criteria other than DILI caused by', 'the IMP. The AstraZeneca Medical Science Director and Global Safety Physician will also be', 'involved in this review together with other subject matter experts as appropriate.', 'According to the outcome of the review and assessment, the Principal Investigator will follow', 'the instructions below.', '86(93)', 'Printed on 3/25/202']\n\n###\n\n", "completion": "END"}